The secretory leukocyte protease inhibitor (SLPI) suppresses cancer cell invasion but promotes blood-borne metastasis via an invasion-independent pathway

Journal of Pathology

Volumn 212, Issue 2, 2007, Pages 152-160

  Sugino, T ^a   Yamaguchi, T ^a   Ogura, G ^a   Kusakabe, T ^a   Goodison, S ^b   Homma, Y ^a   Suzuki, T ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Angiogenesis; Invasion; Metastasis; SLPI

Indexed keywords

MATRIGEL; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL CLONE; CELL MIGRATION; CONTROLLED STUDY; EMBOLISM; ENDOTHELIUM CELL; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LUNG METASTASIS; METASTASIS; MORPHOLOGY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALS; CELL LINE, TUMOR; FEMALE; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; NEOPLASM CIRCULATING CELLS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SERINE PROTEINASE INHIBITORS;

EID: 34249787597     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2156     Document Type: Article

References (22)

1. Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 1987;24:129-209.
2. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572.
3. Sugino T, Kawaguchi T, Suzuki T. Sequential process of blood-borne lung metastases of spontaneous mammary carcinoma in C3H mice. Int J Cancer 1993;55:141-147.
4. Sugino T, Kusakabe T, Hoshi N, Yamaguchi T, Kawaguchi T, Goodison S, et al. An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model. Am J Pathol 2002; 160:1973-1980.
5. Sugino T, Yamaguchi T, Ogura G, Saito A, Hashimoto T, Hoshi N, et al. Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med 2004;2:9.
6. Thompson RC, Ohlsson K. Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci USA 1986; 83:6692-6696.
7. Franten C, Meijer CJ, Dijkman JH. Tissue distribution of antileukoprotease and lysozyme in humans. J Histochem Cytochem 1989;37:493-498.
8. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995;96:456-464.
9. Song X, Zeng L, Jin W, Thompson J, Mizel DE, Lei K, et al. Secretory leukocyte protease inhibitor suppresses the inflammation and joint damage of bacterial cell wall-induced arthritis. J Exp Med 1999;190:535-542.
10. Zhu J, Nathan C, Jin W, Sim D, Ashcroft GS, Wahl SM, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002;111:867-878.
11. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002;277:29999-30009.
12. Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B, et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2003;5:300-310.
13. Ameshima S, Ishizaki T, Demura Y, Imamura Y, Miyamori I, Mitsuhashi H. Increased secretory leukoprotease inhibitor in patients with nonsmall cell lung carcinoma. Cancer 2000;89:1448-1456.
14. Koshikawa N, Nakamura T, Tsuchiya N, Isaji M, Yasumitsu H, Umeda M, et al. Purification and identification of a novel and four known serine proteinase inhibitors secreted by human glioblastoma cells. J Biochem (Tokyo) 1996;119:334-339.
15. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003;100:5778-5782.
16. Kluger HM, Chelouche Lev D, Kluger Y, McCarthy MM, Kiriakova G, Camp RL, et al. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res 2005;65:5578-5587.
17. Preuss TM, Coleman GQ. Human-specific organization of primary visual cortex: alternating compartments of dense Cat-301 and calbindin immunoreactivity in layer 4A. Cerebr Cortex 2002; 12:671-691.
18. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-528.
19. Sun Z, Yang P. Role of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression. Lancet Oncol 2004;5:182-190.
20. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, et al. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metast 2002; 19:193-207.
21. Zhang Y, De Witt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997;99:894-900.
22. Mareel MM, De Baetselier P, Van Roy FM. Mechanisms of Invasion and Metastasis. CRC Press: Boca Raton, FL, 1991.